AAAAAA
Results:
1-13
|
Results: 13
Authors:
LEVENDAG PC
SCHMITZ PI
JANSEN PP
EIJKENBOOM WM
VISSER AG
KOLKMANDEURLOO IKK
SIPKEMA D
VISCH LL
SENAN S
Citation: Pc. Levendag et al., FRACTIONATED HIGH-DOSE-RATE BRACHYTHERAPY IN PRIMARY-CARCINOMA OF THENASOPHARYNX, Journal of clinical oncology, 16(6), 1998, pp. 2213-2220
Authors:
SENAN S
RAMPLING R
GRAHAN MA
WILSON P
ROBIN H
ECKARDT N
LAWSON N
MCDONALD A
VONROEMELING R
WORKMAN P
KAYE SB
Citation: S. Senan et al., PHASE-1 AND PHARMACOKINETIC STUDY OF TIRAPAZAMINE (SR-4233) ADMINISTERED EVERY 3 WEEKS (VOL 3, PG 31, 1997), Clinical cancer research, 3(9), 1997, pp. 1676-1676
Authors:
SENAN S
RAMPLING R
GRAHAM MA
WILSON P
ROBIN H
ECKARDT N
LAWSON N
MCDONALD A
VONROEMELING R
WORKMAN P
KAYE SB
Citation: S. Senan et al., PHASE-I AND PHARMACOKINETIC STUDY OF TIRAPAZAMINE (SR-4233) ADMINISTERED EVERY 3 WEEKS, Clinical cancer research, 3(1), 1997, pp. 31-38
Authors:
DEGRAAFSTRUKOWSKA L
SENAN S
VANPUTTEN WLJ
VANDERZEE J
Citation: L. Degraafstrukowska et al., MALIGNANT PLEURAL MESOTHELIOMA (MM) - OUTCOME FOLLOWING RADIOTHERAPY IN 300 PATIENTS, European journal of cancer, 33, 1997, pp. 433-433
Authors:
SAMSON MJ
DEKOSTE JRV
DEBOER JCJ
TANKINK JJ
VERSTRAATE MBJ
ESSERS M
VISSER AG
SENAN S
Citation: Mj. Samson et al., AN ANALYSIS OF ANATOMIC LANDMARK MOBILITY AND SETUP ERRORS IN RADIOTHERAPY FOR LUNG-CANCER, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 319-319
Authors:
LEVENDAG PC
SCHMITZ PIM
JANSEN PP
SENAN S
EIJKENBOOM WMH
SIPKEMA D
MEEUWIS CA
KOLKMANDEURLOO IK
VISSER AG
Citation: Pc. Levendag et al., FRACTIONATED HIGH-DOSE-RATE AND PULSED-DOSE-RATE BRACHYTHERAPY - FIRST CLINICAL-EXPERIENCE IN SQUAMOUS-CELL CARCINOMA OF THE TONSILLAR FOSSA AND SOFT PALATE, International journal of radiation oncology, biology, physics, 38(3), 1997, pp. 497-506
Authors:
GRAHAM MA
SENAN S
ROBIN H
ECKHARDT N
LENDREM D
HINCKS J
GREENSLADE D
RAMPLING R
KAYE SB
VONROEMELING R
WORKMAN P
Citation: Ma. Graham et al., PHARMACOKINETICS OF THE HYPOXIC CELL CYTOTOXIC AGENT TIRAPAZAMINE ANDITS MAJOR BIOREDUCTIVE METABOLITES IN MICE AND HUMANS - RETROSPECTIVEANALYSIS OF A PHARMACOKINETICALLY GUIDED DOSE-ESCALATION STRATEGY IN A PHASE-I TRIAL, Cancer chemotherapy and pharmacology, 40(1), 1997, pp. 1-10
Authors:
LEVENDAG PC
VERMEY J
SENAN S
Citation: Pc. Levendag et al., THE HISTORY OF RADIOTHERAPY IN THE NETHERLANDS, International journal of radiation oncology, biology, physics, 35(3), 1996, pp. 615-622
Authors:
SENAN S
Citation: S. Senan, VASOACTIVITY, A POTENTIALLY IMPORTANT VARIABLE IN THE SEQUENCING OF TIRAPAZAMINE (SR-4233) AND RADIATION, International journal of radiation oncology, biology, physics, 31(1), 1995, pp. 209-209
Authors:
ROBIN H
SENAN S
WORKMAN P
GRAHAM MA
Citation: H. Robin et al., DEVELOPMENT AND VALIDATION OF A SENSITIVE SOLID-PHASE-EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ASSAY FOR THE BIOREDUCTIVE AGENT TIRAPAZAMINE AND ITS MAJOR METABOLITES IN MOUSE AND HUMAN PLASMA FORPHARMACOKINETICALLY GUIDED DOSE-ESCALATION, Cancer chemotherapy and pharmacology, 36(3), 1995, pp. 266-270
Authors:
DOHERTY N
HANCOCK SL
KAYE S
COLEMAN CN
SHULMAN L
MARQUEZ C
MARISCAL C
RAMPLING R
SENAN S
ROEMELING RV
Citation: N. Doherty et al., MUSCLE CRAMPING IN PHASE-I CLINICAL-TRIALS OF TIRAPAZAMINE (SR-4233) WITH AND WITHOUT RADIATION, International journal of radiation oncology, biology, physics, 29(2), 1994, pp. 379-382
Authors:
SENAN S
Citation: S. Senan, THE RADIOBIOLOGICAL BASIS OF CONCOMITANT CISPLATIN AND RADIOTHERAPY, International journal of radiation oncology, biology, physics, 27(2), 1993, pp. 483-484
Authors:
SENAN S
Citation: S. Senan, NASOPHARYNGEAL AND NASAL MALIGNANT-LYMPHOMA, Histopathology, 22(4), 1993, pp. 407-407
Risultati:
1-13
|